PNT2258: Interim Phase II data

Interim data from 37 patients with relapsed or refractory DLBCL in the open-label, U.S. and Puerto Rican Phase II Wolverine trial showed that once-daily 120 mg/m 2 IV PNT2258 on

Read the full 303 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE